Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial

This article was originally published here

In the late-stage trial called IKEMA, Sarclisa, when added to carfilzomib and dexamethasone, met the primary endpoint by delivering significantly prolonged progression-free survival compared to standard of care

The post Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply